The Impact of the Fecal Microbiome on Cancer Immunotherapy Afaf E. G. OsmanJason J. Luke Current Opinion 02 January 2019 Pages: 1 - 7
Current Ebola Virus Vaccine Progress Andrea MarziChad E. Mire Leading Article 02 January 2019 Pages: 9 - 14
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases Anniina T. VirtanenTeemu HaikarainenOlli Silvennoinen Review Article Open access 30 January 2019 Pages: 15 - 32
Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies Paula J. BusseHenriette FarkasMarc A. Riedl Review Article Open access 12 December 2018 Pages: 33 - 43
Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities Bhagirathbhai R. DholariaChristina A. BachmeierFrederick Locke Review Article 17 December 2018 Pages: 45 - 60
Monoclonal Antibodies for Multiple Sclerosis: An Update Jonas GrafOrhan AktasHans-Peter Hartung Review Article 02 January 2019 Pages: 61 - 78
Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial Chang-Hee SuhDae Hyun YooSung Young Lee Original Research Article Open access 05 February 2019 Pages: 79 - 91
A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects Tan ZhangGuihong ChenYi Fang Original Research Article 03 December 2018 Pages: 93 - 100
Comparison of the Pharmacokinetic–Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers Seokuee KimTaegon HongJung-Ryul Kim Original Research Article Open access 01 December 2018 Pages: 101 - 112
FKB327: An Adalimumab Biosimilar Zaina T. Al-Salama Adis Biosimilar Brief 02 February 2019 Pages: 113 - 116
Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar Sheridan M. Hoy Adis Biosimilar Brief 30 January 2019 Pages: 117 - 120
Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?” Sarfaraz K. Niazi Letter to the Editor 02 January 2019 Pages: 121 - 123
